Published in Leukemia on January 01, 2006
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (2011) 0.86
Portal hypertension and myeloproliferative neoplasms: a relationship revealed. ISRN Hematol (2013) 0.77
Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets (2013) 0.75
Pulmonary extramedullary haematopoiesis. BMJ Case Rep (2011) 0.75
Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica (2010) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Chronic lymphocytic leukemia. N Engl J Med (1995) 4.52
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol (2001) 2.75
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38
Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol (1994) 2.20
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol (2008) 2.01
Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer (1998) 1.97
Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood (1998) 1.93
Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol (1998) 1.81
Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med (1998) 1.79
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia (2008) 1.77
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia (2007) 1.67
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol (2002) 1.61
Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol (1991) 1.59
Effect of reduced gravity on the preferred walk-run transition speed. J Exp Biol (1997) 1.58
[Pulmonary cavitation as the initial manifestation of Hodgkin's disease]. Med Clin (Barc) (1994) 1.47
p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood (1998) 1.45
A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol (1989) 1.44
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.42
[Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography]. Sangre (Barc) (1996) 1.41
Central nervous system involvement demonstrated by immunological study in prolymphocytic variant of chronic lymphocytic leukemia. Acta Haematol (1989) 1.41
Non-Hodgkin's lymphoma associated with Gaucher's disease. Leuk Lymphoma (1998) 1.41
Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia (1998) 1.39
The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival. Haematologica (1999) 1.39
[Extrabronchial small-cell carcinoma: apropos 6 cases]. Med Clin (Barc) (1993) 1.39
Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia (1996) 1.39
Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart (2007) 1.38
Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol (1998) 1.37
PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood (1994) 1.36
Functions of intermediate filaments. Cell Motil Cytoskeleton (1989) 1.33
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol (1986) 1.29
Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer (1991) 1.28
Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol (2003) 1.24
Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol (1995) 1.24
Central nervous system involvement in mantle cell lymphoma. Ann Oncol (2007) 1.22
Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood (1997) 1.22
Sex differences in mortality of people who visited emergency rooms for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.19
The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol (2006) 1.18
High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol (1999) 1.16
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood (1996) 1.16
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia (2012) 1.14
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia (2006) 1.13
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood (1999) 1.11
Chronic lymphocytic leukemia: a changing natural history? Leukemia (1997) 1.10
Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia (1999) 1.10
Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood (1984) 1.08
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia (2008) 1.06
Pan-atlantic analysis of the overlap of a highly migratory species, the leatherback turtle, with pelagic longline fisheries. Proc Biol Sci (2014) 1.05
Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol (1992) 1.05
cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. Cancer Res (1998) 1.03
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol (2010) 1.03
Association between educational level and health related quality of life in Spanish adults. J Epidemiol Community Health (1999) 1.02
Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia (2001) 1.01
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int J Cancer (2000) 1.01
Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study. Am J Clin Pathol (1991) 1.00
Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer (1988) 0.99
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant (2004) 0.99
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol (2002) 0.98
Criteria for severe aplastic anaemia. Lancet (1987) 0.98
Vimentin's tail interacts with actin-containing structures in vivo. J Cell Sci (1994) 0.98
Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol (1996) 0.98
[Aspergillus endocarditis in a patient with acute lymphoblastic leukemia in remission]. Med Clin (Barc) (1983) 0.97
Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol (1998) 0.97
Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol (2001) 0.97
c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia (1999) 0.96
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia (2005) 0.95
Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia (2008) 0.94
Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia (2002) 0.93
Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol (1999) 0.93
Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol (1999) 0.93
Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol (1997) 0.92
Identification and characterization of Drosophila melanogaster paramyosin. J Mol Biol (1991) 0.92
INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol (2000) 0.91
Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia. Leuk Lymphoma (2001) 0.91
Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia (2006) 0.91
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol (2004) 0.91
Xanthogranulomatous pyelonephritis and systemic amyloidosis: report of 2 new cases and the natural history of this association. J Urol (1991) 0.90
Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol (1999) 0.90
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia (2013) 0.90
Ultrasound of the pancreas: update and controversies. Eur Radiol (2001) 0.90
Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica (2000) 0.89
Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant (1999) 0.89
Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma (1996) 0.89
Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol (1998) 0.88
Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol (1994) 0.88
Specific cutaneous involvement in Hodgkin's disease. Hematol Oncol (1992) 0.87
[Applications for bronchial blockers in thoracic surgery]. Rev Esp Anestesiol Reanim (2007) 0.87
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia (2011) 0.87